TY - JOUR
T1 - Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease
AU - Gobara, Hideo
AU - Nakatsuka, Atsuhiro
AU - Shimizu, Kanichiro
AU - Yamanaka, Takashi
AU - Matsui, Yusuke
AU - Iguchi, Toshihiro
AU - Hiraki, Takao
AU - Yamakado, Koichiro
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Purpose: To evaluate the safety and efficacy of cryoablation for renal cell carcinoma (RCC) in patients with stage 4 or 5 non-dialysis chronic kidney disease (CKD). Materials and methods: This retrospective multicenter study included patients with maximum tumor diameter ≤ 4 cm, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m 2 , in whom cryoablation was performed percutaneously with curative intent between July 2011 and May 2016. Results: Of 541 patients who underwent renal tumor cryoablation, 17 (3.1%; 4 women, 13 men; mean age 70.1 ± 10.6 years) with stage 4 or 5 non-dialysis CKD were included in this study. The pre-cryoablation eGFR was 22.5 ± 6.3 ml/min/1.73 m 2 . The mean tumor diameter was 2.8 ± 0.7 cm. No Grade 3 or higher adverse events occurred post-cryoablation. The eGFR at each time point was significantly lower than that before treatment. One patient required hemodialysis initiation at 21 months post-procedure. None of the patients showed residual RCC at their last follow-up. Conclusion: Cryoablation of RCC is safe in patients with stage 4 or 5 non-dialysis CKD and yields treatment results comparable to those in patients without CKD. This treatment could be completed without the early initiation of hemodialysis after the procedure.
AB - Purpose: To evaluate the safety and efficacy of cryoablation for renal cell carcinoma (RCC) in patients with stage 4 or 5 non-dialysis chronic kidney disease (CKD). Materials and methods: This retrospective multicenter study included patients with maximum tumor diameter ≤ 4 cm, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m 2 , in whom cryoablation was performed percutaneously with curative intent between July 2011 and May 2016. Results: Of 541 patients who underwent renal tumor cryoablation, 17 (3.1%; 4 women, 13 men; mean age 70.1 ± 10.6 years) with stage 4 or 5 non-dialysis CKD were included in this study. The pre-cryoablation eGFR was 22.5 ± 6.3 ml/min/1.73 m 2 . The mean tumor diameter was 2.8 ± 0.7 cm. No Grade 3 or higher adverse events occurred post-cryoablation. The eGFR at each time point was significantly lower than that before treatment. One patient required hemodialysis initiation at 21 months post-procedure. None of the patients showed residual RCC at their last follow-up. Conclusion: Cryoablation of RCC is safe in patients with stage 4 or 5 non-dialysis CKD and yields treatment results comparable to those in patients without CKD. This treatment could be completed without the early initiation of hemodialysis after the procedure.
KW - Chronic kidney disease
KW - Cryoablation
KW - Kidney
KW - Renal cell carcinoma
KW - Stage 4
UR - http://www.scopus.com/inward/record.url?scp=85064270385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064270385&partnerID=8YFLogxK
U2 - 10.1007/s11604-019-00821-7
DO - 10.1007/s11604-019-00821-7
M3 - Article
C2 - 30941617
AN - SCOPUS:85064270385
SN - 1867-1071
JO - Japanese Journal of Radiology
JF - Japanese Journal of Radiology
ER -